[Intractable ulcer].
Yoshida
Yukio
Y
Department of Internal Medicine I, Saitama Medical School, Saitama Medical Center.
Miyatani
Hiroyuki
H
Tokuyama
Tetu
T
Hirakawa
Ryuichi
R
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D003937:Diagnosis, Differential; D004351:Drug Resistance; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011379:Prognosis; D054328:Proton Pump Inhibitors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole